Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.

IF 3.1 3区 医学 Q1 ECONOMICS
European Journal of Health Economics Pub Date : 2024-12-01 Epub Date: 2024-03-07 DOI:10.1007/s10198-024-01672-4
Aixue Zhang, Jing Li, Zhuxin Mao, Zitong Wang, Jing Wu, Nan Luo, Peng Liu, Pei Wang
{"title":"Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.","authors":"Aixue Zhang, Jing Li, Zhuxin Mao, Zitong Wang, Jing Wu, Nan Luo, Peng Liu, Pei Wang","doi":"10.1007/s10198-024-01672-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess and compare the measurement properties of EQ-5D-5L and SF-6Dv2 among lymphoma patients in China.</p><p><strong>Methods: </strong>A face-to-face survey of Chinese lymphoma patients was conducted at baseline (all types) and follow-up (diffuse large B-cell). EQ-5D-5L and SF-6Dv2 health utility scores (HUSs) were calculated using the respective Chinese value sets. Ceiling effect was assessed by calculating the percentage of respondents reporting the optimal health state. Convergent validity of EQ-5D-5L and SF-6Dv2 was assessed using the Spearman rank correlation coefficient (r) with QLQ-C30 as a calibration standard. Known-groups validity of the two HUSs was evaluated by comparing their scores of patients with different conditions; and their sensitivity was further assessed in the known-groups using relative efficiency (RE). Test-retest reliability and responsiveness was tested using ICC and standardized response mean (SRM), respectively.</p><p><strong>Results: </strong>Altogether 200 patients were enrolled at baseline and 78 were followed up. No ceiling effect was found for SF-6Dv2 compared to 24.5% for EQ-5D-5L. Correlation between the two HUSs and with QLQ-C30 score was strong (r > 0.5). Each dimension of EQ-5D-5L and SF-6Dv2 had moderate or greater correlations with similar dimensions of QLQ-C30 (r > 0.35). Both EQ-5D-5L and SF-6Dv2 could only a minority known-groups, and the latter may have better sensitivity. EQ-5D-5L had better test-retest reliability (ICC = 0.939); while both of them were responsive to patients with worsened and improved clinical status.</p><p><strong>Conclusions: </strong>EQ-5D-5L and SF-6Dv2 were found to have good convergent validity and responsiveness, while EQ-5D-5L had better test-retest reliability and higher ceiling effect. Not enough evidence indicates which of the two measures has better known-group validity and sensitivity.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-024-01672-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To assess and compare the measurement properties of EQ-5D-5L and SF-6Dv2 among lymphoma patients in China.

Methods: A face-to-face survey of Chinese lymphoma patients was conducted at baseline (all types) and follow-up (diffuse large B-cell). EQ-5D-5L and SF-6Dv2 health utility scores (HUSs) were calculated using the respective Chinese value sets. Ceiling effect was assessed by calculating the percentage of respondents reporting the optimal health state. Convergent validity of EQ-5D-5L and SF-6Dv2 was assessed using the Spearman rank correlation coefficient (r) with QLQ-C30 as a calibration standard. Known-groups validity of the two HUSs was evaluated by comparing their scores of patients with different conditions; and their sensitivity was further assessed in the known-groups using relative efficiency (RE). Test-retest reliability and responsiveness was tested using ICC and standardized response mean (SRM), respectively.

Results: Altogether 200 patients were enrolled at baseline and 78 were followed up. No ceiling effect was found for SF-6Dv2 compared to 24.5% for EQ-5D-5L. Correlation between the two HUSs and with QLQ-C30 score was strong (r > 0.5). Each dimension of EQ-5D-5L and SF-6Dv2 had moderate or greater correlations with similar dimensions of QLQ-C30 (r > 0.35). Both EQ-5D-5L and SF-6Dv2 could only a minority known-groups, and the latter may have better sensitivity. EQ-5D-5L had better test-retest reliability (ICC = 0.939); while both of them were responsive to patients with worsened and improved clinical status.

Conclusions: EQ-5D-5L and SF-6Dv2 were found to have good convergent validity and responsiveness, while EQ-5D-5L had better test-retest reliability and higher ceiling effect. Not enough evidence indicates which of the two measures has better known-group validity and sensitivity.

中国淋巴瘤患者EQ-5D-5L和SF-6Dv2的心理测量性能。
目的:评估并比较中国淋巴瘤患者EQ-5D-5L和SF-6Dv2的测量特性:方法:对中国淋巴瘤患者进行基线(所有类型)和随访(弥漫大 B 细胞)面对面调查。EQ-5D-5L和SF-6Dv2健康效用评分(HUSs)采用相应的中文值集进行计算。通过计算报告最佳健康状况的受访者百分比来评估上限效应。以 QLQ-C30 为校准标准,使用斯皮尔曼等级相关系数 (r) 评估 EQ-5D-5L 和 SF-6Dv2 的收敛效度。通过比较不同病情患者的得分,评估了两种 HUS 的已知组有效性;并使用相对效率(RE)进一步评估了已知组的敏感性。采用 ICC 和标准化反应平均值(SRM)分别检验了测试再测可靠性和反应性:共有 200 名患者参与了基线研究,78 人接受了随访。SF-6Dv2 未发现上限效应,而 EQ-5D-5L 为 24.5%。两种 HUSs 和 QLQ-C30 评分之间的相关性很强(r > 0.5)。EQ-5D-5L和SF-6Dv2的每个维度与QLQ-C30的相似维度都有中等或更大的相关性(r > 0.35)。EQ-5D-5L和SF-6Dv2都只适用于少数已知群体,后者可能具有更好的灵敏度。EQ-5D-5L具有更好的测试-再测可靠性(ICC = 0.939);而两者对临床状况恶化和改善的患者都有反应:结论:研究发现EQ-5D-5L和SF-6Dv2具有良好的收敛效度和反应性,而EQ-5D-5L具有更好的重测可靠性和更高的上限效应。没有足够的证据表明这两种测量方法中哪一种具有更好的已知组有效性和敏感性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
2.30%
发文量
131
期刊介绍: The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics: • Basics of health economic approaches and methods • Pharmacoeconomics • Health Care Systems • Pricing and Reimbursement Systems • Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements. Officially cited as: Eur J Health Econ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信